In this open label study we evaluated the efficacy of Levetiracetam (LEV) in the long-term treatment of 15 patients (7 males, 8 females, age range 4-40 years, mean 22.53 years) with drug-resistant symptomatic epilepsies. Our data showed that LEV is an efficacious and safe antieplleptic drug in this group of subjects.
|Translated title of the contribution||Efficacy of Levetiracetam in the long-term treatment of drug-resistant symptomatic epilepsies|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 2005|
ASJC Scopus subject areas
- Clinical Neurology